{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Pegloticase', 'Pegloticase will be administered (per FDA approved guidelines) as an admixture of 8 mg in 250 mL of 0.45% or 0.9%', 'Sodium Chloride Injection, USP for IV infusion over a target infusion time of 120 minutes by gravity feed or infusion', 'pump. Pegloticase will not be administered as an IV push or bolus. Standardized IR prophylaxis consisting of pre-', 'treatment with antihistamines and corticosteroids will accompany each infusion. The drug name, dose, and timing of', 'these prophylactic medications will be recorded.', 'Participants will not be fasting on the day of infusion; they will be encouraged to have a snack or normal meal 1 hour', 'before, or immediately after, the infusion. Prior to pegloticase infusion participants will receive infusion prophylaxis (e.g.', 'oral fexofenadine (60 mg) the night before and fexofenadine (60 mg/PO) and acetaminophen (1000 mg/PO) the morning', 'of the infusion; and hydrocortisone IV (200 mg) immediately prior to the infusion).', 'In a patent IV site, using tubing with no in-line filter, the drug preparation will be infused over approximately 120', 'minutes (within 15 minutes) while the participant is under close observation for any signs of distress. Administration of', 'drug will be immediately discontinued if respiratory distress, agitation, chest or back pain, urticaria, or another clinically', 'significant event occurs during infusion. If the adverse event (AE) meets the definition of an serious adverse event (SAE),', 'the infusion may not be restarted under any circumstances. A SAE will be reported within 24 hour or sooner to the Data', 'Safety Monitoring Board (DSMB). If the AE does not meet the definition of an SAE, the site PI may make the decision to', 're-start the infusion depending upon the nature and severity of the AE.', 'Infusions subsequent to an infusion-related reaction in an individual participant may be given in a larger volume of', 'diluent, not to exceed 500 mL. In such a case, the infusion duration will also be extended to a minimum of 3 hours. The', 'total volume and duration of infusion will be captured in the medical record and CRF.', 'As a precaution, emergency equipment will be readily available to treat a possible hypersensitivity reaction, and will', 'include drugs that would be used to treat an anaphylactic reaction. Personnel fully trained in advanced cardiopulmonary', 'resuscitation and in the use of the emergency equipment will be readily available during, and for 1 hour after, the', 'infusion. At the end of the infusion, the IV line will be flushed with 10 mL of normal saline to assure the full dose is', 'administered. As IRs can occur after completion observation of participants for approximately an hour post-infusion will', 'be performed.', '7.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY OF STUDY DRUGS', '7.2.1 ACQUISITION AND ACCOUNTABILITY', 'Pegloticase will be shipped by Horizon Pharma, PLC to the study sites. The UAB IDS Pharmacy will be responsible for the', 'storage, over-encapsulation, and shipment of mycophenolate mofetil and placebo pills for this study. MMF will be', 'purchased in bulk quantity through the UAB Investigational Drugs Pharmacy, which will also oversee the process of over-', 'encapsulation with cellulose of the active medication and placebos, handle medication storage, distribution, and', 'assignment of randomization sequence. A drug log will be used to track the study drug from pharmacy to each', 'randomized study participant. The centralized management of the medication will allow maintenance of a double-blind', 'trial. Adherence to the medication will be recorded by pill counts at the follow-up study visits and consumption of at', 'least 80% will be required to consider the participant compliant. A non-compliant participant will continue in the study', 'and enter analyses as mandated by statistician. Further questions about pharmacy activities can be directed to: Chris', 'Chapleau, PharmD; IDS Pharmacy, University of Alabama at Birmingham Hospital, 205-934-7191.', '11']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Supplies and medication vials used in preparing medications will be discarded as waste immediately after product', 'preparation. The waste is incinerated on-site at UAB Hospital and UM hospital. In addition, incineration is the method of', 'destruction for expired, returned and unused product at study closure. When a study is closed or closed to enrollment', '(and no participants are being treated), sites will have 60 days to document destruction of unused product.', '7.2.2 FORMULATION, APPEARANCE, PACKAGING, AND LABELING', 'Mycophenolate Mofetil (MMF)', 'MMF, the immune modulator for the study, is the 2-morpholinoethyl ester of moiety mycophenolic acid (MPA), and is', 'an inosine monophosphate dehydrogenase (IMPDH) inhibitor. The chemical name for MMF is 2-morpholinoethyl (E)-6-', '(1,3-dihydro- 4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. Ithas an empirical', 'formula of C23H31NO7. MMF will be purchased by UAB from Besse Medical (West Chester Township, OH). MMF capsules', 'include croscarmellose sodium, magnesium stearate, povidone (K-90) and pregelatinized starch. The MMF capsule shells', 'contain black iron oxide, FD&C blue #2, gelatin, red iron oxide, silicon dioxide, sodium lauryl sulfate, titanium dioxide,', 'and yellow iron oxide. All MMF capsules will be over-encapsulated with cellulose to match compounded placebo.', 'Favorable pharmacokinetic properties of the encapsulation process have been consistently noted with other substances.', 'Blinded study drug labeling will be annotated with the protocol number by the research pharmacist. The UAB site', 'pharmacy will maintain an inventory of drug supplies received and dispensed.', 'Pegloticase', 'Pegloticase ( Krystexxa) is a clear, colorless, sterile solution in phosphate-buffered saline intended for IV infusion after', 'dilution and will be supplied by Horizon Pharma, PLC. Pegloticase is commercially available in the US in a single-use, 2 mL', 'glass vial with a Teflon coated (latex-free) rubber injection stopper. Each mL of pegloticase contains 8 mg of uricase', 'protein conjugated to 24 mg of 10 kDa monomethoxypoly (ethylene glycol). Excipients include disodium hydrogen', 'phosphate dihydrate, sodium chloride, sodium dihydrogen phosphate dehydrate, and water for injection. All', 'participants in the study will receive pegloticase at the same dose of 8 mg administered IV every 2 weeks for a total of 6', 'infusions over a 12-week treatment period, and over an additional 12-week pegloticase opt-in follow-up period (per', 'standard of care). Study drug labeling will be annotated with the protocol number.', '7.2.3 PRODUCT STORAGE AND STABILITY', 'Mycophenolate Mofetil (MMF)', 'MMF has demonstrated teratogenic effects in rats and rabbits, therefore MMF tablets should not be opened or crushed.', 'Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in MMF tablet/capsules.', 'Pegloticase', 'Before preparation for use, pegloticase will be stored in the carton, maintained under refrigeration between 2\u00b0C and', '8\u00b0C (36\u00b0F and 46\u00b0F), protected from light, and will not be shaken or frozen. Investigational clinical supplies will be', 'received by a designated person at each study site, handled and stored safely and properly, and kept in a secured', 'location to which only the Investigator and designated assistants have access. Clinical supplies will be dispensed only in', 'accordance with the protocol. We will keep accurate records of the clinical supplies received and, the amount dispensed', 'for each participant, and the amount remaining at the conclusion of the study. We will mark the label of any vials that', 'are not to be used with a large \"X,\" and document the reason for rejecting them on the drug accountability log. In', 'accordance with good pharmacy practice, gloves will be worn during preparation of the dose.', '12']\n\n###\n\n", "completion": "END"}